BMO Capital initiates Tenet Healthcare stock with Market Perform rating

BMO Capital initiated Tenet Healthcare coverage at Market Perform with a $265 price target, citing its expanding ambulatory surgery business, operational improvements and potential for mid- to high-single-digit long-term EBITDA growth. The firm views much of the favorable outlook as reflected in Tenet's roughly 7x valuation, though the stock's 10.25 P/E and 0.15 PEG suggest value relative to growth prospects. Other analysts have recently raised targets as high as $308 following better-than-expected Q2 2026 performance, higher EBITDA forecasts and raised guidance.

Analysis

THC’s upside now depends less on incremental multiple expansion and more on whether its ambulatory platform can convert growth investments into sustained margin gains. The key competitive advantage is mix: shifting procedures toward ASCs should reduce labor intensity and capital requirements relative to acute-care operators such as HCA and CYH, while high-acuity hospital positioning preserves pricing power in services that cannot migrate outpatient. If this model holds, THC can sustain superior free-cash-flow conversion even if hospital volume growth slows.

The near-term setup is less attractive than the stream of target-price revisions suggests. Supplemental-payment assumptions and operational-improvement estimates can create a favorable earnings bridge over the next 1-3 quarters, but those benefits are vulnerable to state-program changes, reimbursement timing, and labor-cost reacceleration; they should not be capitalized as recurring ASC earnings. The non-controlling-interest adjustment also matters: investors should focus on FCF attributable to THC shareholders rather than headline consolidated EBITDA, where ASC economics may be overstated.

Consensus appears to be treating hospital and ASC execution as independently additive. The contrarian risk is that capital deployed to expand ambulatory capacity cannibalizes profitable hospital outpatient revenue before fixed hospital costs can be resized, compressing consolidated margins during the transition. Over 6-18 months, a premium valuation is justified only if USPI-type same-facility revenue growth, case mix, and attributable EBITDA outpace hospital EBITDA—not merely if aggregate guidance rises.

Key Decisions for Investors

• Do not chase THC solely on analyst-target momentum; initiate only on a pullback toward a level offering at least 15% upside to a revised base-case valuation, after confirming attributable FCF and ASC same-facility metrics in the next earnings release.
• For a 3-6 month relative-value expression, consider long THC / short CYH in equal dollar amounts. THC has the stronger outpatient-growth and execution profile, while CYH has materially greater balance-sheet sensitivity; exit if THC’s hospital labor expense rises faster than revenue or if CYH deleveraging materially beats expectations.
• Use HCA as the cleaner sector hedge rather than a directional short: long THC / short HCA is appropriate only if the next quarter demonstrates ASC EBITDA growth exceeding hospital EBITDA growth and guidance is raised without greater reliance on supplemental payments.
• Set a downside thesis trigger at any reduction in state supplemental-payment visibility, a miss in attributable EBITDA/FCF despite consolidated EBITDA growth, or evidence that ASC expansion is diluting hospital margins. Those outcomes would warrant closing longs rather than averaging down.
• Watch upcoming reimbursement and state directed-payment developments over the next 1-3 months; absent disclosure separating recurring operating improvement from program-related support, treat the earnings-upgrade cycle as an alert rather than a fresh standalone catalyst.